A screening colonoscopy is one of the few things Medicare pays for in full, with no deductible and no coinsurance, as long as nothing is found. The moment the doctor spots a polyp and snips it out during the same session, the billing can shift from a preventive screening to a therapeutic operation, and a share of the cost lands on the patient. It is a quirk that catches retirees who scheduled a routine test expecting to owe nothing and left owing a coinsurance on a growth they never knew was there. The mechanics of that switch are worth understanding before the appointment, not after the statement arrives.
The screening that costs nothing
Part B covers screening colonoscopies with no out-of-pocket cost when the provider accepts assignment, and there is no minimum age required to qualify for the benefit. For most beneficiaries considered at average risk, Medicare pays for the test once every 120 months, or once every 48 months following a prior flexible sigmoidoscopy. The screening sits inside a much broader set of preventive services Medicare fully funds, all built on the same idea of catching disease early enough that it becomes far cheaper, and far more survivable, to treat.
Colorectal cancer is among the most preventable of all cancers precisely because a colonoscopy can find and remove precancerous polyps years before they ever turn malignant. Waiving the cost is meant to strip away any financial reason a beneficiary might have to skip the test, especially older adults who sit in the highest-risk age band and stand to gain the most. The trouble is structural: the same instrument that screens can also treat in the same pass, and Medicare’s rules handle those two acts on very different financial terms.
That design reflects a tension the program has never fully resolved. A test heavily promoted as free is also, by its nature, the test most likely to find something worth removing, and finding something is the entire clinical point of doing it. The clean preventive-coverage promise therefore holds up neatly only in the cases where the colonoscopy comes back completely clear, which are not the same cases where the procedure does a patient the most lasting good.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. Our free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
How a screening becomes a procedure
If the physician finds and removes a polyp or other tissue during the exam, the visit is reclassified on the spot. The beneficiary then pays 15 percent of the Medicare-approved amount for the provider’s services, a reduced coinsurance that lawmakers phased in specifically because so many screenings end in exactly such a removal. The Part B deductible does not apply to the charge, but the 15 percent share on a specialist’s fee together with a facility charge can still add up to real money, reaching into the hundreds of dollars for a single procedure.
Polyps are common in older adults, so the reclassification is not some rare edge case; it is a frequent and even expected outcome of a test working exactly as it was intended to work. A patient who arrives for what is billed as a clean preventive screening has no way to know in advance whether a polyp will be found and removed, which means the final size of the bill is effectively decided on the exam table rather than at the scheduling desk weeks earlier.
The 15 percent figure is itself the softened version of a harsher earlier rule. Screenings that ended in a removal once carried the full 20 percent coinsurance that applies to most other Part B services, and the reduced rate is now scheduled to keep shrinking over the next several years until it eventually reaches zero. Until that phase-in finishes, though, the charge remains entirely real, and a beneficiary who reads only the word free in the brochure can still be caught genuinely off guard.
What patients can do about the surprise
The reclassified screening is different from a diagnostic colonoscopy, which is ordered because of symptoms or a prior finding and carries cost-sharing right from the start. A beneficiary weighing a flexible sigmoidoscopy or another screening option faces the same underlying principle: the test is preventive and free until the moment something is actually removed. Asking the provider ahead of time how a polyp removal would be coded can at least keep the eventual bill from arriving as a complete shock.
Documentation is where these particular disputes tend to be won or lost. When a bill arrives that looks larger than the patient expected, the coding on it is what determines whether the visit was billed as a screening with a removal or as a full diagnostic procedure, and errors in that coding are not at all unheard of. A beneficiary who understands the distinction going in is far better positioned to question a charge that does not match what actually happened during the exam.
The reduced coinsurance is meaningfully gentler than the rate it replaced and is set to keep fading, yet it will not vanish entirely for several more years. Until it does, the program is left holding an awkward contradiction: promising a free test in its outreach while quietly charging for that test’s single most useful result. That tension keeps some cost-conscious retirees hesitating over a screening that was designed, above all, to save their lives.
This article was researched and drafted with the assistance of artificial intelligence.
More Financial Reading
